Lanreotide In Polycystic Kidney Disease Study
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Lanreotide In Polycystic Kidney Disease Study is a clinical trial[1].
Key Facts
- Lanreotide In Polycystic Kidney Disease Study is in the country of France[2].
- Lanreotide In Polycystic Kidney Disease Study's instance of is recorded as clinical trial[3].
- Lanreotide In Polycystic Kidney Disease Study's start time is recorded as +2014-09-19T00:00:00Z[4].
- Lanreotide In Polycystic Kidney Disease Study's end time is recorded as +2019-09-30T00:00:00Z[5].
- Lanreotide In Polycystic Kidney Disease Study's sponsor is recorded as Assistance Publique – Hôpitaux de Paris[6].
- Lanreotide In Polycystic Kidney Disease Study's number of participants is recorded as {'unit': '1', 'amount': '+156'}[7].
- Lanreotide In Polycystic Kidney Disease Study's title is recorded as Lanreotide In Polycystic Kidney Disease Study[8].
- Lanreotide In Polycystic Kidney Disease Study's short name is recorded as LIPS[9].
- Lanreotide In Polycystic Kidney Disease Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
- Lanreotide In Polycystic Kidney Disease Study's ClinicalTrials.gov ID is recorded as NCT02127437[11].
- Lanreotide In Polycystic Kidney Disease Study's research intervention is recorded as lanreotide[12].
- Lanreotide In Polycystic Kidney Disease Study's clinical trial phase is recorded as phase III clinical trial[13].
- Lanreotide In Polycystic Kidney Disease Study's research site is recorded as Necker–Enfants Malades Hospital[14].
- Lanreotide In Polycystic Kidney Disease Study's research subject recruitment status is recorded as completed[15].
- Lanreotide In Polycystic Kidney Disease Study's study type is recorded as interventional study[16].